Anti-Inflammatory and Anti-Oxidant Activity of Portulaca oleracea Extract on LPS-Induced Rat Lung Injury by Baradaran Rahimi, Vafa et al.
molecules
Article
Anti-Inflammatory and Anti-Oxidant Activity of
Portulaca oleracea Extract on LPS-Induced Rat
Lung Injury
Vafa Baradaran Rahimi 1,2,†, Hassan Rakhshandeh 1,†, Federica Raucci 3, Benedetta Buono 3,
Reza Shirazinia 4 , Alireza Samzadeh Kermani 5, Francesco Maione 3,*, Nicola Mascolo 3 and
Vahid Reza Askari 1,6,*
1 Pharmacological Research Center of Medicinal Plants, Mashhad University of Medical Sciences,
Mashhad 9177948564, Iran; baradaranv941@mums.ac.ir (V.B.R.); rakhshandehh@mums.ac.ir (H.R.)
2 Department of Pharmacology, Faculty of Medicine, Mashhad University of Medical Sciences,
Mashhad 9177948564, Iran
3 Department of Pharmacy, School of Medicine and Surgery, University of Naples Federico II, Via Domenico
Montesano 49, 80131 Naples, Italy; federicaraucci@gmail.com (F.R.); bened.buono@gmail.com (B.B.);
nicola.mascolo@unina.it (N.M.)
4 Department of Pharmacology, Faculty of Veterinary Medicine, University of Tehran, Tehran 1419963111,
Iran; Rezashirazinia@ut.ac.ir
5 Department of Chemistry, Faculty of Science, University of Zabol, Zabol 35856-98613, Iran;
arsamzadeh@yahoo.com
6 Neurogenic Inflammation Research Centre, Mashhad University of Medical Sciences,
Mashhad 9177948564, Iran
* Correspondence: francesco.maione@unina.it (F.M.); askariv941@mums.ac.ir or
Vahidrezaaskary@yahoo.com (V.R.A.); Tel.: +39-081678429 (F.M.); +98-513-8002-262 (V.R.A.);
Fax: +98-513-8828564 (V.R.A.)
† These authors share first co-authorship.
Received: 16 December 2018; Accepted: 26 December 2018; Published: 1 January 2019


Abstract: Acute lung injury (ALI) and acute respiratory distress syndrome (ARDS) are classified
as two lung complications arising from various conditions such as sepsis, trauma, and lung
inflammation. Previous studies have shown that the extract of the leaves of Portulaca oleracea (PO)
possesses anti-inflammatory and anti-oxidant activities. In the present study, the effects of PO
(50–200 mg/kg) and dexamethasone (Dexa; 1.5 mg/kg) on lipopolysaccharide (LPS)-induced ALI
were investigated. Subsequentially, the lung wet/dry ratio; white blood cells (WBC); levels of nitric
oxide (NO); myeloperoxidase (MPO); malondialdehyde (MDA); thiol groups formation; super oxide
dismutase (SOD) and catalase (CAT) activities; and levels of interleukin (IL)-1β, tumor necrosis
factor (TNF)-α, IL-6, IL-10, prostaglandin E2 (PGE2), and transforming growth factor (TGF)-β in the
broncho alveolar lavage fluid (BALF) were evaluated in order to demonstrate the anti-oxidant and
anti-inflammatory activity of PO. Our results show that PO suppresses lung inflammation by the
reduction of IL-β, IL-6, TNF-α, PGE2, and TGF-β, as well as by the increase of IL-10 levels. We also
found that PO improves the level of WBC, MPO, and MDA, as well as thiol group formation and SOD
and CAT activities, compared with the LPS group. The results of our investigation also show that
PO significantly decreased the lung wet/dry ratio as an index of interstitial edema. Taken together,
our findings reveal that PO extract dose-dependently displays anti-oxidant and anti-inflammatory
activity against LPS-induced rat ALI, paving the way for rational use of PO as a protective agent
against lung-related inflammatory disease.
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1. Introduction
Inflammation plays a dual protective and damaging role against cellular and tissue damages.
Acute inflammation is usually considered a protective role to destroy and remove the noxious stimuli
and injured tissues, thereby allowing the tissue repair. When this process becomes uncontrolled,
another face of inflammation appears. In this regard, acute lung injury (ALI) and acute respiratory
distress syndrome (ARDS) are known as two inflammatory lung complications with a high rate of
morbidity and mortality [1,2]. These are characterized by severe pulmonary inflammation, massive
recruitment of neutrophils and lymphocytes in interstitial tissue, edema, disruption of epithelial
integrity, and the injury of lung parenchyma [3]. ALI and ARDS result from various diseases and
pathological conditions such as trauma, pneumonia, sepsis, and endotoxemia [4,5].
Despite the great efforts to find new and/or most active pharmacological approaches for
ALI/ARDS treatment and the discovery of the pathological factors, their mortality still presents
a high rate (about of 40%) [6,7]. On this basis, the need for new therapeutic agents in the field of
lung inflammatory-based diseases has prompted the investigation of several plant-based products
for potential therapeutic application [8,9]. Portulaca oleracea (PO) belongs to the Portulacaceae
family, commonly called qurfeh (Persia), purslane (the USA and Australia), pigweed (England),
rigla (Egypt), pourpier (France), and Ma-Chi-Xian (China) [10]. This plant is commonly found
in tropical and subtropical areas of the world, as well as in many regions of the United States,
Mediterranean, and tropical Asian countries [11]. It has been used as a folk medicine in many countries
for its febrifuge, antiseptic, and anthelmintic properties [12]. Congruently, it has been reported
that PO exhibits great pharmacological properties including anti-oxidant [13], antibacterial [14],
anti-ulcerogenic [15], anti-inflammatory [16], and wound-healing properties [17,18]. Indeed, recent
studies have demonstrated that Oleracone, an alkaloid isolated from PO, attenuates inflammation
induced by lipopolysaccharide (LPS) in RAW 264.7 macrophage cell lines [19] and that the extract
of the leaves of PO possesses anti-inflammatory and immunomodulatory properties on Th1/Th2
lymphocytes profile [20]. It has also been reported that treatment of ovalbumin-sensitized rats with
PO extract displays a modulation of lung inflammation and immune markers [21].
Lipopolysaccharide (LPS) is known as the predominant microbial inducer of inflammation
processes accountable for the strong innate immune responses in ALI onset [5,22]. Alveolar epithelial
cells (AECs) are the first cells faced by pathogenic microorganisms playing a central role in the
beginning and progression of acute lung injury, followed by massive recruitment of neutrophils and
lymphocytes [2,23]. Moreover, it has also been demonstrated that inflammation, due to inflammatory
cyto-chemokines (in particular interleukin (IL)-6 and tumor necrosis factor (TNF)-α), plays an
important role in lung injury onset [24,25] and the first innate immune response [26]. Therefore, in the
present study, we aimed to investigate a new possible medication regarding the anti-inflammatory
properties of PO for ALI using the LPS-induced animal model of ALI and lung inflammation. In the
present study, we extended the previous observations about protective effects of PO, and shed new
light on its anti-inflammatory and anti-oxidant mechanism of action.
2. Results
2.1. Effects of LPS and PO on Body and Absolute Organ Weights, and Lung Wet/Dry Ratio
LPS (5 mg/kg) significantly elevated the absolute organs weights (lung, p ≤ 0.001; liver p ≤ 0.01;
and heart, p ≤ 0.001) compared with the control group (Table 1). PO at doses of 50 mg/kg (p ≤ 0.01),
100 mg/kg (p ≤ 0.001), and 200 mg/kg (p ≤ 0.001), as well as Dexa (1.5 mg/kg, p ≤ 0.001) significantly
attenuated the absolute lung weight compared with the LPS group (Table 1). Moreover, PO (200
mg/kg) and Dexa (1.5 mg/kg) notably decreased the increased absolute weights of liver (p ≤ 0.01)
and heart (p ≤ 0.001) compared with the LPS group (Table 1). LPS at 5 mg/kg significantly increased
lung wet/dry ratio compared with the control group (Figure 1, p ≤ 0.001). PO at doses of 100 mg/kg
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(p ≤ 0.05) and 200 mg/kg (p ≤ 0.001) and Dexa (p ≤ 0.001) at 1.5 mg/kg significantly reverted the lung
wet/dry ratio increase compared with the LPS group (Figure 1).
Table 1. Body and absolute organs weights for different groups.
C LPS Dexa PO 50 mg/kg PO 100 mg/kg PO 200 mg/kg
Body weight (g) 220 ± 31 218 ± 22 208 ± 19 215 ± 21 223 ± 22 231 ± 19
Lung (g) 1.05 ± 0.08 *** 2.78 ± 0.15 1.28 ± 0.07 *** 1.87 ± 0.14 ** 1.61 ± 0.09 *** 1.23 ± 0.11 ***
Liver (g) 5.41 ± 1.21 ** 7.94 ± 1.24 5.77 ± 1.06 ** 8.01 ± 1.28 7.23 ± 1.18 5.69 ± 1.13 **
Heart (g) 0.86 ± 0.08 *** 1.21 ± 0.09 0.89 ± 0.12 *** 1.17 ± 0.07 1.05 ± 0.17 0.83 ± 0.12 ***
Data are presented as means ± SD (n = 6). ** p ≤ 0.01 and *** p ≤ 0.001. PO—Portulaca oleracea.
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Figure 1. Effect of Portulaca oleracea (PO) extract on the lung wet/dry ratio in broncho alveolar lavage 
fluid (BALF). Data were presented as mean ± standard error of measurement (SEM) (n = 6). +++ p ≤ 
0.001 compared with the control group, * p ≤ 0.05 and *** p ≤ 0.001 compared with the 
lipopolysaccharide (LPS) group, and # p ≤ 0.05 compared with the Dexa + LPS group. 
2.2. Effects of LPS and PO on Bronchoalveolar Lavage Fluid (BALF) Hematologic Indices 
Our results revealed that LPS treatment significantly modified hematologic indices of 
neutrophil, basophil, eosinophil, and monocyte/macrophage, as well as total white blood cells (Figure 
2A–E, p ≤ 0.001) and lymphocytes (Figure 2F, p ≤ 0.001). Notably, PO extract (100 and 200 mg/kg) and 
Dexa (1.5 mg/kg) markedly reverted hematologic indices (Figure 2A–E, p ≤ 0.05 to 0.001) and 
lymphocytes reduction (Figure 2F, p ≤ 0.001). 
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Figure 1. Effect of Portulaca oleracea (PO) extract on the lung wet/dry ratio in broncho alveolar
lavage fluid (BALF). Data w re presented as mea ± standard error of measurement (SEM) (n = 6).
+++ p ≤ 0.001 compared with the control group, * p ≤ 0.05 and *** p ≤ 0.001 compared with the
lipopolysaccharide (LPS) group, and # p ≤ 0.05 compared with the Dexa + LPS group.
2.2. Effects of LPS and PO on Bronchoalveolar Lavage Fluid (BALF) Hematologic Indices
Our results revealed that LPS treatment significantly modified hematologic indices of neutrophil,
basophil, eosinophil, and monocyte/macrophage, as well as total white blood cells (Figure 2A–E,
p ≤ 0.001) and lymphocytes (Figure 2F, p ≤ 0.001). Notably, PO extract (100 and 200 mg/kg) and Dexa
(1.5 mg/kg) marke ly reverted hema ologic indices (Figure 2A–E, p ≤ 0.05 to 0.001) and lymph cytes
reduction (Figure 2F, p ≤ 0.001).’
2.3. Effects of LPS and PO Extract on BALF Inflammatory Cytokines
LPS significantly increased the production of inflammatory cytokines including IL-1β (Figure 3A,
p ≤ 0.001), TNF-α (Figure 3B, p ≤ 0.001), IL-6 (Figure 3C, p ≤ 0.001), IL-10 (Figure 3D, p ≤ 0.05), PGE2
(Figure 3E, p ≤ 0.001), and TGF-β (Figure 3F, p ≤ 0.001) compared with the control group. Treatment
with Dexa at 1.5mg/kg significantly decreased all measured parameters compared with the LPS
group (Figure 3A–F, p ≤ 0.01 to 0.001 for all cases). Interestingly, PO at doses of 100 and 200 mg/kg
significantly modulated the expression of IL-1β, TNF-α, IL-6, PGE2, and TGF-β, and the increase of
increment in IL-10 level compared with the LPS group (Figure 3A–F, p ≤ 0.05 to 0.001 for all cases).
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Figure 2. Effect of PO extract on hematologic indices (A) neutrophil, (B) basophil, (C) eosinophil,
(D) total whit blood cell, (E) monocyte/macrophage ratio, and (F) lymphocyte in BALF. Data were
presented as mean ± SEM (n = 5). +++ p ≤ 0.001 compared with the control group, * p ≤ 0.05 and
*** p ≤ 0.001 compared with the LPS-induced group and # p ≤ 0.05 and ### p ≤ 0.001 compared with
the Dexa + LPS group. WBC—white blood cells.
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Figure 3. Effects of PO extract on inflammatory and anti-inflammatory biomarkers (A) interleukin
(IL)-1β, (B) TNF-α, (C) IL-6, (D) IL-10, (E) PGE2, and (F) TGF-β in BALF. Data were resented as mean
± SEM (n = 7). + p ≤ 0.05 and +++ p ≤ 0.001 compare with the control grou ; * p ≤ 0.05, ** p ≤ 0.01,
and *** p ≤ 0.001 compared with the LPS-induced group; and # p ≤ 0.05, ## p ≤ 0.01, and ### p ≤ 0.001
compared with the Dexa + LPS group.
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2.4. Impact of PO on the BALF Oxidant/Antioxidant Status
LPS notably increased malondialdehyde (MDA), myeloperoxidase (MPO), and nitric oxide (NO)
levels, and contextually decreased super oxide dismutase SOD and catalase (CAT) activity, as well
as thiol content, compared with the control group (Figure 4A–C, p ≤ 0.001). However, PO (100
and 200 mg/kg) and Dexa (1.5 mg/kg) groups significantly decreased MDA, MPO, and NO levels
(Figure 4A–C, p ≤ 0.05 to 0.001) and reverted oxidant/anti-oxidant status that resulted in a significant
increase in the levels of SOD (p ≤ 0.001) and catalase (p ≤ 0.001) activity, as well as total thiol content
(p ≤ 0.001) (Figure 5).
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Figure 4. Effects of PO extract on oxidative indices: (A) malondialdehyde (MDA), (B) myeloperoxidase
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compared with the control group, * p ≤ 0.05 and *** p ≤ 0.001 compared with the LPS-induced group,
a # p ≤ 0.05 compared with the Dexa + LPS group.
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Figure 5. Effects of PO extract on anti-oxidative indices: (A) SOD, (B) thiol, and (C) catalase (CAT)
in BALF and lung tissue. Data were presented as mean ± SEM (n = 6). +++ p ≤ 0.001 compared with
the control group, *** p ≤ 0.001 compared with the LPS-induced group, # p 0.05 and ### p ≤ 0.001
compared with the Dexa + LPS group.
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2.5. Characteristics of PO Hydro-Ethanolic Extract
HPLC peaks from PO extract chromatogram appeared at 320 nm (Figure 6B). Using the H-NMR
method, we also detected the peaks at 220 and 320 nm between 8 and 12 min ascribed to kaempferol
and apigenin derivatives, respectively (Figure 6A,B).
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3. Discussion
LPS, as a gram-negative bacterial constituent, is a well-known and established cause of
adventitious pneumonia from the community or hospital patients, and Toll-like receptor-4 (TLR4)
activation by this stimuli is a reasonable way for activat ng the innate immu ity ag inst gram-negative
pathogen/ [27,28]. It has been demonstra ed that LPS leads to pulmonary inflammation such as
ALI, which occurs after 4–48 h of pathog n exposure [29–31]. For this reason, previous studies have
reported that LPS stimulation is standard odel for inducing experimental ALI nd ARDS [32,33].
Inflammation is consid ed the major response t inf ctions or injur es. However, uncontrolled
prolongation of the inflammat ry repertoire may lead to tissue damage and heali g [24,28].
LPS activated macrophages produce inflammatory mediators such as TNF-α, PGE2, IL-1β,
and IL-6 [34–36], which play an i portant role in self-sustaining inflammatory conditions [37].
Therefore, suppressing the prolonged and/or chronic lung inflammation induced by LPS could
represent a p tential cu ative aspect for lung injury [38,39].
Portul ca oleracea is a medicinal plant widely used in tra al medicin [40]. Nowadays,
many studies have revealed its valuable pharmacologic properties includi g anti-inflammatory,
anti-oxidant, anti-microbial, and neuroprotective [41–48]. PGE2 is a bioactive lipid associating with
inflammation and c ncer. Its synthesis is or ginated by phosph lipases (PLAs) through liberating free
fatty acids from membrane, including arachid n acid (AA) [49]. There re several studies on he
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notion of the contribution of the dysregulation in the levels of arachidonic acid, and PGE2 synthesis or
degradation have been associated with a number of inflammatory diseases [49–51]. In the current study,
we demonstrated that LPS significantly increases the levels of PGE2 and other inflammatory cytokines
in the BALF compared with the control group. Previous studies also described that an increase in the
level of PGE2 promotes the activation of both the innate and adaptive immunity including macrophage
and Th17 cells, a subset of CD4+ helper T cells, by the production of interleukin-17 (IL-17) [49–51].
Our results showed that PO suppresses lung inflammation by the reduction of IL-1β, IL-6, TNF-α,
PGE2, and TGF-β, as well as by the increase of IL-10 levels. These results are in accordance with
previous studies that reported anti-inflammatory effects of PO on RAW 264.7 macrophage cell line
and human umbilical vein endothelial cells (HUVECs) treated with LPS [16,52]. In contrast, it has
been reported that PO extract inhibits TNF-α-induced adhesion of HL-60 cells to HUVECs and mRNA
expression of IL-8 and monocyte chemoattractant protein (MCP)-1 [12]. It has also been suggested
that inhibition of inflammation by PO may be partly because of modulation of nuclear factor-kappa B
(NF-κB) signaling pathway and decrement of p65 nuclear accumulation [53]. Indeed, all these pieces
of evidence further support and validate the anti-inflammatory potential of Portulaca oleracea in other
inflammatory-based illness such as colitis [54], peripheral pain [16], and liver injury [55]. Previous
studies demonstrated that the levels of inflammatory (TNF-α and IL-1β) and anti-inflammatory (IL-10)
cytokines are impressed by both transcription factors NF-κB and nuclear factor erythroid 2-related
factor 2 (Nrf2), respectively [28,56,57]. As one of the current study’s limitations, we did not evaluate
changes in gene expression and/or activity of certain transcription factors related to the inflammatory
and antioxidant response such as NFκB and Nrf2, respectively.
TLR-4, as the main receptor for LPS, possesses an essential role in the pathogenesis of ALI,
also supported by its localization on airway vascular endothelial and epithelial cells [58]. Accordingly,
Askari and coworkers [20] have shown that PO extract had modulatory effects on imbalanced
lymphocytes through the reduction of inflammatory cytokines and increased expression of IL-10
may be correlated to TLR-4 modulation. LPS-induced lung injury is also characterized by neutrophils
infiltration in lung tissues that occurs and is driven by the massive cytokines production [2,59,60].
Interestingly, we found that PO extract improves the level of WBC in BALF samples, as well as the level
of MPO, compared with the LPS group as an index of a significative reduction of neutrophil recruitment
and activity. Contextually, in ALI/ARDS onset, lung edema appears as a consequence of microvascular
leakage associated with endothelial injury [61,62]. The results of our study showed that PO significantly
decreased the lung wet/dry ratio as an index of interstitial edema. In addition, we observed that PO
markedly prevented MDA and NO production as well as propagated thiol, catalase, and SOD in BALF.
Lipid peroxidation is a condition under which free radicals attack lipids containing carbon–carbon
double bonds leading to cell and organ damage [63–65]. The main bio-products produced in
this process are MDA and SOD, widely used as lipid peroxidation index and as markers of lipid
peroxidation in ALI/ARDS [66]. Furthermore, it has been suggested that NO and inducible nitric oxide
synthase (iNOS) lead to oxidative stress and endothelial damage [63–65,67]. Therefore, inhibition of
iNOS and reduction of NO content could be beneficial in these pathologies [68]. Free radicals are
highly reactive species capable of destructing DNA, proteins, carbohydrates, and lipids, structurally
leading to cell damage or apoptosis. Exogenous anti-oxidant enzymes such as catalase, SOD, and thiol
groups protect cells against oxidative stress damages induced by free radicals [69–73]. It could be
concluded that the significant modulation of SOD and catalase activities and of the level of thiol groups
after PO treatments improve the lung antioxidant status in an LPS-induced rat lung injury.
The anti-oxidant and anti-inflammatory properties of this plant extract may be the result of the
considerable amounts of anti-oxidant compounds including gallotannins, omega-3 fatty acids, ascorbic
acid, α-tocopherols, kaempferol, quercetin, and apigenin [16,74,75], and because of the presence
of flavonoids such as kaempferol and apigenin derivatives found in our chemical characterization.
Accordingly, Chen et al. reported that aqueous extract of PO alleviated high fat diet-elicited oxidative
stress including blood and liver anti-oxidant enzymatic systems by the modulation of leptin and liver
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peroxisome proliferator-activated receptor (PPAR)-γ [13,28]. Furthermore, it has been reported that
aqueous extract of PO exhibits cytoprotective effects on 2,2′-azobis hydrochloride-induced hemolytic
injuries of red blood cells (RBCs) [76].
4. Materials and Methods
4.1. Chemicals and Reagents
LPS (Escherichia coli 055: B5) was obtained from Sigma (St. Louis, MO, USA). Myeloperoxidase
(MPO) assay kit, IL-1β, TNF-α, IL-6, IL-10, PGE2, and TGF-β enzyme-linked immunosorbent
assay (ELISA) kit were provided by eBioscience (San Diego, CA, USA). All other reagents were
of analytical grade.
4.2. Preparation of PO Extract
PO extract was prepared according to our previously characterized and standardized method [20].
In brief, the hydroethanolic extract was made using the macerated method with 70% w/w ethanol for
72 h at room temperature (RT). The yield of the dried extract was 21% w/w in the ratio of dried powder,
and kept in −20 ◦C until use. For the characterization of PO extract, we used a liquid chromatography
system comprising of a 510 Waters pump (Waters Association, Milford, MA, U.S.A.), a variable
wavelength (model 486 Waters UV detector), and a Waters sample injection system (U6K system).
The mobile phase was formed by a mixture of methanol:acetonitrile/tetrahydrofuran/0.5% glacial
acetic acid (5:3:18:74). This phase was filtered under vacuum, then degassed, and finally pumped
through the Novapak C18 column (150× 3.9 mm i.d.) at a flow rate of 1.0 mL/min. The chromatograms
were recorded at 220 and 320 nm [62] and interpreted by Gloexir Pars ® Company, Mashhad, Iran.
For total flavonoid content, we have followed the procedure previously adopted in our group [63,64].
Briefly, 5 mL of 2% aluminum trichloride (AlCl3) in methanol was mixed with the same volume
of PO extract, incubated for 15 min at RT, and then measured at 510 nm using a MultiSpec UV-vis
spectrophotometer (Shimadzu, Tokyo, Japan). The total flavonoid content was measured based on the
standard curve of different flavonoids at a range of 0–50 µg/mL.
4.3. Animals and Husbandry
Adult male Sprague–Dawley rats (weighing 220 ± 30 g) were provided by the animal laboratory
of Faculty of Medicine, Mashhad University of Medical Sciences (Mashhad, Iran), and kept in an
animal care facility under controlled temperature and humidity, and on a 12 h/12 h light/dark cycle,
with ad libitum access to water and a standard laboratory chow diet. All experimental procedures
were carried out in compliance with local and national law and policies (Grant No. 971254 of Ethical
Committee of National Institute for Medical Research Development, Iran). All procedures were carried
out to minimize the number of animals (n = 5–7 per group) and their suffering.
4.4. Experimental Protocol
Animals were randomly divided into six groups of 5–7 rats: (I) control group (saline); (II) LPS
group (5 mg/kg); (III) LPS + Dexamethasone group (Dexa, 1.5 mg/kg); (IV) LPS + PO (50 mg/kg)
group; (V) LPS + PO (100 mg/kg) group; and (VI) LPS + PO (200 mg/kg) group. LPS was administered
using intraperitoneal (i.p.) injection to induce acute lung injury. PO and Dexa were administrated by
oral gavage (po) 1 h before LPS injection. Dose adjustment was performed according to our preliminary
study. Rats were sacrificed, and samples were collected at 4 h after LPS administration [61].
4.5. Absolute Organ Weight and Lung Wet/dry Weight Ratio
The whole body and absolute lung, heart, and liver weights were recorded. The measurement
of water content of lungs was also carried out by assessing the wet/dry weight quantitative ratio of
lung tissues. Briefly, the right lung inferior lobe was dissected and weighed to supply the ‘wet’ weight.
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The lung was then dried at −80 ◦C for 72 h to get the ‘dry’ weight. Finally, the wet/dry ratio was
calculated as wet/dry ratio = wet weight/dry weight.
4.6. Broncho-Alveolar Lavage Fluid (BALF) Preparation
As previously described [64], animals were anesthetized with urethane (50 mg/kg, i.p.) at the end
of the experimental protocol. Successively, the chest was opened and lungs and trachea were dissected
and washed with distilled water. Lungs were lavaged with 1 mL saline five times at controlled RT
through the cannulated trachea. The collected BALF was centrifuged at 2500 g for 10 min and the
obtained supernatant was stored at −80 ◦C for the subsequent analysis.
4.7. Measurement of Total and Differential White Blood Cells (WBC) in BALF
Briefly, 1 mL of BALF was stained with Turk solution (1 mL glacial acetic acid, 1 mL of gentian
violet solution 1%, and 100 mL distilled water) and counted by Neubauer chamber. Differential
cell analysis was carried out by the aim of a light microscope as previously described [77]. WBC
and differential WBC were determined via light microscope according to morphological criteria
and staining.
4.8. Oxidant-Antioxidant Assessment in BALF
For measurement of malondialdehyde (MDA) concentration, the sample was refluxed with a
solution of HCl and TBA (thiobarbituric acid). Then, 2 mL of this solution was added to 1 mL of
BALF and heated in a water bath at 50 ◦C for 40 min to dissolve TBA. After cooling and reaching
RT, it was centrifuged at 1000 rpm for 10 min. Afterward, the absorbance was read at 535 nm and
then the MDA concentration was calculated based on the following equation: C (M) = A/1.65 × 105,
where C indicated the concentration and A the absorbance [24,78]. To determine the thiol groups,
the DTNB method (2, 2′-dinitro-5, 5′-dithiodibenzoic acid) was used. This reagent reacts with SH
(thiol) groups and produces a yellow complex that has an absorbance peak at 412 nm and has a molar
absorption coefficient of 13.6 mM−1cm−1. Then, 1 mL of Tris-EDTA buffer (pH 8.6) was added to
50 µL BALF and sample absorbance was read at 412 nm against Tris-EDTA buffer alone (A1). A total
of 20 µL of DTNB reagents (10 nM in methanol) was added to the mixture and the samples were
kept at RT for 15 min, after which the absorbance was read again (A2). The absorbance of DTNB
reagent was also read as a blank (B) [78]. Total thiol concentration expressed as nmol/mg protein was
calculated with the following equation: (A2 − A1 − B) × 1.07/0.05 × 13.6. Catalase (CAT) activity
was measured based on its ability to decompose hydrogen peroxide (H2O2) by decreasing adsorption
in a 240 nm absorption spectrum. For this purpose, 30 mM hydrogen peroxide was used as a substrate
and 50 mM phosphate buffer with pH = 7 as substrate substitute in blank solution. The measuring
solution contained a suitable volume of sample and a solution of hydrogen peroxide. The reaction
was started by adding hydrogen peroxide and reduced absorption by spectrophotometer at 240 nm
for 3 min. Each catalase activity unit was defined as the hydrogen peroxide µmol consumed per
mg of protein [78]. Measurement of superoxide dismutase enzyme activity was performed based on
previously described methods with slight modifications [63,64,79–81]. The method is based on the
pyrogallol auto-oxidation and the inhibition of superoxide-dependent reduction of the tetrazolium
dye, MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) to its formazan. The reaction
was stopped by adding dimethyl sulfoxide (DMSO), and then performed with a microtiter plate reader
at 570 nm. A unit of SOD was defined as the amount of enzyme needed to control MTT reduction up
to 50%.
4.9. Enzyme-Linked Immunosorbent Assay (ELISA) Assay
The levels of TNF-α, IL-6, IL-1β, IL-10, PGE2, and TGF-β in the supernatants of obtained BALF
were measured using commercially available enzyme-linked immunosorbent assay kit (ELISA kits,
eBioscience Co., San Diego, CA, USA) according to the manufacturer instructions. Briefly, 100 µL
Molecules 2019, 24, 139 10 of 14
of BALF supernatants, diluted standards, quality controls, and dilution buffer (blank) were applied
on a pre-coated plate with the monoclonal antibody for 2 h. After washing, 100 µL of biotin-labeled
antibody was added and incubation continued for 1 h. The plate was washed and 100 µL of the
streptavidin–HRP conjugate was added and the plate was incubated for a further 30 min period in the
dark. The addition of 100 µL of the substrate and stop solution represented the last steps before the
reading of absorbance (measured at 450 nm) on a microplate reader [82].
4.10. Myeloperoxidase Assay
Leukocyte myeloperoxidase (MPO) activity was assessed by measuring the H2O2-dependent
oxidation of 3,3′,5,5′-tetramethylbenzidine (TMB) as previously reported [82]. Aliquots of 20 µL of
BALF were incubated with 160 µL of TMB and 20 µL of H2O2 (in 80 mM phosphate buffer, pH 5.4) in
96-well plates. Plates were incubated for 5 min at RT and optical density was read at 620 nm using
a plate-reader (Biorad, Italy). The assay was performed in duplicates and normalized for protein
content [82].
4.11. Statistical Analysis
The results obtained were expressed as the mean ± SEM. Normality test was carried out based
on Kolmogorov–Smirnov. After passing the tests, statistical analysis was performed using one-way
analysis of variance (ANOVA) followed by Bonferroni or Dunnett’s post-test when comparing more
than two groups. Student’s t-test was used in cases where two groups were compared. Statistical
analysis was performed using GraphPad Prism 6.0 software (San Diego, CA, USA). Data were
considered statistically significant when a value of p ≤ 0.05 was achieved. The data and statistical
analysis comply with the recommendations on experimental design, analysis [83], and data sharing
and presentation in preclinical pharmacology [84,85].
5. Conclusions
These studies are in accordance with our findings that demonstrate the protective effects of PO on
LPS-induced acute rat lung injury, paving the way for rational use of this plant extract in lung-related
inflammatory diseases, as well as in those characterized by an increase of free radicals and oxidative
reactive products.
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